DoW Toxic Exposures Clinical Trial Award
This grant funds clinical trials to advance prevention, treatment, or management of health issues caused by military-related toxic exposures, encouraging collaborative projects between clinicians and researchers.
Funder: Dept. of the Army -- USAMRAA
Due Dates (Anticipated): November 2026 (Full application / submission deadline, projected)
Funding Amounts: Estimated total program funding: $4,500,000; expected 1 award; no cost sharing required
Summary: Supports clinical trials on prevention, treatment, or management of conditions associated with military-related toxic exposures.
Key Information: Partnering Principal Investigator Option available to encourage interdisciplinary collaboration.
Description
This opportunity supports the advancement, execution, and analysis of clinical trials aiming to significantly impact the prevention, treatment, or management of symptoms, diseases, or conditions linked to military-related toxic exposures. Projects may range from small proof-of-concept trials (such as pilot, first-in-human, or phase 0 studies) to large-scale or pragmatic clinical trials focused on efficacy in relevant patient populations. The program emphasizes meaningful interdisciplinary partnerships, particularly through the Partnering Principal Investigator Option (PPIO), which allows for collaborations between clinicians and research scientists, with each PI potentially receiving a separate award if the application is successful. The intent is to accelerate the translation of promising interventions or knowledge products into clinical applications.
